ArticleJournal of molecular histology2026
Protective effects of rosmanol on DEN-induced lung cancer via targeting Nrf2/NF-κB/PI3K/Akt and COX-2/CYP2E1/VEGF pathways: in vivo approach.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lung cancer (LC) remains the foremost cause of cancer-related mortality worldwide. Exposure to the carcinogen diethylnitrosamine (DEN) results in significant toxicity across various organs, with the lungs being especially affected. Rosmanol (RML), a well-known phenolic diterpenoid derived from several medicinal plants, especially Rosmarinus officinalis L. (rosemary), has been reported to exhibit potent anti-proliferative, antioxidant, anti-inflammatory, and anticancer activities. Therefore, the present-day study investigated the antineoplastic potential of RML in contrast to DEN-induced LC in a Wistar rat model by modulating the Nrf2/NF-κB/PI3K/Akt and COX-2/CYP2E1/VEGF signalling pathways. Rats were categorised into six experimental groups: normal control (NC), DEN (150 mg/kg b.w., i.p.), DEN + RML at different concentrations, and RML alone (20 mg/kg b.w.). The findings revealed that RML administered DEN-induced rat decreased BW, elevation in LW and LW/BW ratio, hepatic enzyme leakage, serum glycoproteins, oxidative stress, inflammation, and structural disruption of pulmonary and hepatic tissues. In addition, RML enhanced antioxidant enzyme activities, lung tissue glycoproteins, and the expression of Nrf2, IL-10, p53, Bax, and caspases, while significantly suppressing Bcl-2, inflammatory cytokines, COX-2, CYP2E1, and VEGF mRNA levels. The RML-alone group exhibited biochemical and histological profiles similar to those of the NC group. Collectively, the results suggest that RML confers strong antitumor protection against DEN-induced LC, primarily through its antioxidant, anti-inflammatory, and pro-apoptotic actions via regulation of the Nrf2/NF-κB/PI3K/Akt signalling network.
Indexed as
Identifiers
41729379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.